Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

New England Journal of Medicine

Volumn 338, Issue 21, 1998, Pages 1488-1497

  Théroux, Pierre ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPORTIONAL HAZARDS MODELS; TYROSINE;

EID: 2642599026     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805213382102     Document Type: Article

References (28)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
2. Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205.
3. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
6. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
7. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
8. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
10. Théroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996;94:899-905.
11. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996;94:2083-9.
12. Theroux P, White H, David D, et al. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994;90:Suppl:I-231. abstract.
13. Simoons ML, de Boer MJ, van der Brand MJBM, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
14. Egbertson MS, Chang CTC, Duggan ME, et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37:2537-51.
15. Gould RJ, Chang CT-C, Lynch RJ, et al. MK-0383 is a potent nonpeptide mimic of RGD that inhibits glycoprotein IIb/IIIa. Thromb Haemost 1993;69:976. abstract.
16. Peerlinck K, De Leperleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88:1512-7.
17. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trail, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-54.
18. Braunwald E, Mark DB, Jones HR, et al. Unstable angina: diagnosis and management. Clinical practise guidline no. 10. Washington, D.C.: Government Printing Office, 1994. (AHCPR publication no. 94-0602.)
19. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat unstable angina. N Engl J Med 1988;319:1105-11.
20. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous herapin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
21. Rizik DG, Healy S, Margulis A, et al. A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol 1995;75:993-7.
22. Braunwald E. Unstable angina: a classification. Circulation 1989;80: 410-4.
23. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus herapin for unstable angina. N Engl J Med 1998;338:1498-505.
24. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-206.
25. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;276:811-5.
26. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
27. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight herapin with unfractionated herapin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
28. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.